GlassScriptPhysician profile
Christopher David Rankin
NPI 1023427267
$4,834.49
in general payments reported to CMS, 2019-2025
25 companies · $41.94 in 2025
The $41.94 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $770 · 2020: $338 · 2021: $885 · 2022: $1,032 · 2023: $1,001 · 2024: $766 · 2025: $41.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,808.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $771.56 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $621.28 | 2019-2024 | |
| Abbvie INC. | $546.90 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $455.11 | 2019-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Janssen Pharmaceuticals, INC | $430.75 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $418.42 | 2019-2024 | Lokelma, Andexxa |
| Merck Sharp & Dohme LLC | $294.16 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| E.R. Squibb & Sons, L.L.C. | $264.18 | 2019-2024 | Eliquis |
| Gilead Sciences, INC. | $159.83 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $155.45 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.35 | 2020-2023 | Xifaxan |
| Alexion Pharmaceuticals, INC. | $96.26 | 2019-2024 | Ultomiris |
| Novo Nordisk INC | $94.31 | 2019-2024 | Ozempic, Rybelsus |
| Sunovion Pharmaceuticals INC. | $92.65 | 2019 | |
| Boston Scientific Corporation | $56.06 | 2021-2024 | Watchman Flx |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $36.74 | 2022 | |
| Paratek Pharmaceuticals, INC. | $30.82 | 2022 | |
| Philips North America LLC | $27.02 | 2021-2022 | |
| Amgen INC. | $26.81 | 2022 | |
| Abiomed | $26.42 | 2023 | Impella |
| Bioxcel Therapeutics, INC. | $23.10 | 2023 | Igalmi |
| Bayer Healthcare Pharmaceuticals INC. | $21.20 | 2024 | |
| Allergan, INC. | $18.72 | 2019 | |
| Electromed, INC. | $13.79 | 2023 | Smartvest |
| Shire North American Group INC | $13.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Rankin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.